Early experience of inclisiran: real-world analysis of utilization and lipid-lowering effects

29 August 2025 (16:15 - 17:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Associate Professor Ann Marie Navar

University of Texas Southwestern Medical Center, Dallas (United States of America)

7 More presentations in this session

Presentation thumbnail

The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan

Professor P. Liu (Tainan, TW)

Abstract Slides Video

Presentation thumbnail

Prospective validation of a self-report-based model for coronary artery calcium screening and assessment of treatment gaps in lipid-lowering therapy.

Doctor E. Hagberg (Gothenburg, SE)

Abstract Slides Video

Presentation thumbnail

BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects

Ms Y. Li (Shanghai, CN)

Abstract Slides Video

Presentation thumbnail

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM

Professor M. Miller (Philadelphia, US)

Abstract Slides Video

Presentation thumbnail

PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease

Doctor A. Bosch (Erlangen, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Drug therapy (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 16:15 CET

You may be interested in

Congress Presentation

Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service

Congress Presentation

Real-world evidence or real-world reality - Is Real world evidence a mirror or magnifier of RCTs?

Congress Presentation

Inclisiran: a breakthrough in LDL-C reduction for indian ASCVD patients

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources